What pharmacy technicians say would actually make them feel seen on World Pharmacy Technician Day, and the other 364 days of the year.
|Articles|June 12, 2023
Drugs to Watch: Current Clinical Trials in Hematology/Oncology
Author(s)Lauren Biscaldi, MS
Advertisement
The oncology pipeline is robust, according to Andrea Prince, PharmD, BCACP, a hematology/oncology clinical pharmacist at Northwestern Medicine. During her presentation at the 2023 American Society of Health-System Pharmacists (ASHP) Summer Meetings and Exhibition, Prince reviewed several notable drugs in the pipeline, including several that are first in class therapies and others with a novel mechanism of action.
References
Rim MH, Prince A. Specialty pharmacy pipeline updates I: Expansion of hematology/oncology therapies. Presented at: 2023 American Society of Health-System Pharmacists Summer Meetings and Exhibition; June 10-14, 2023; Baltimore, MD.
Erba H, Montesinos P, Vrhovac R, et al. Quizartinib prolonged survival vs placebo plus intensive induction and consolidation therapy followed by single- agent continuation in patients aged 18-75 yaers with newly diagnosed FLT3-ITD+ AML. Presented at: European Hematology Congress 2022; June 9-12, 2022; Vienna, Austria.
https://library.ehaweb.org/eha/2022/eha2022-congress/356965/harry.erba.quizartinib.prolonged.survival.vs.placebo.plus.intensive.induction.html Verstovesk S, Gerds AT, Vannucchi AM, et al; MOMENTUM Study Investigators. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomized, controlled, phase 3 study. Lancet. 2023;401(10373):269-280. doi:10.1016/S0140-6736(22)02036-0
Dasari NA, Lonardi S, Garcia-Carbonero R, et al. FRESCO-2: A global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruqintinib in patients with refractory metastatic colorectal cancer. Annals of Oncology. 2022;33 (suppl_7):S808-S869. doi:10.1016/annonc/annonc1089
Talquetamab generates high response rate in relapsed or refractory multiple myeloma. The ASCO Post. December 11, 2022. Updated Decmeber 19, 2022. Accessed June 12, 2023.
https://ascopost.com/news/december-2022/talquetamab-generates-high-response-rate-in-relapsed-or-refractory-multiple-myeloma/ Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387(24):2220-2231. doi:10.1056/NEJMoa2206913
Mellinghoff IK, Van Den Bent MJ, Clarke JL. INIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation. J Clin Oncol 38: 2020 (suppl; abtsr TPS2574). doi:10/1200/JCO.2020.38.15_suppl.TPS2574
Mellinghoff IK, Van Den Bent MJ, Blumenthal DT. INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation. J Clin Oncol 41, 2023 (suppl 17; abstr LBA1). doi:10.1200/JCO.2023.41.17_suppl.LBA1
Advertisement
Related to this article
The analysis is not a head-to-head trial, and the weight loss gap reached statistical significance under 1 of 2 estimands.
A 1.6-million-birth analysis finds that adoption of a 2016 trial's antibiotic protocol climbed sharply in US hospitals, with a drop in infection rates.
New findings suggest semaglutide's benefits may extend well beyond diabetes and weight loss and into airway disease and mood disorders.
First approved for adults in 2022, the therapy is now cleared for adults and pediatric patients weighing 66 lbs or more with symptomatic obstructive hypertrophic cardiomyopathy.
With the inherent value medications provide in the greater health care system, Jennifer Hammons, PharmD, DrPH, argues that rural pharmacies deserve the proper recognition.
A claims analysis of 2031 patients aged 10 to 17 years found that nutrition counseling was infrequent and often began months after treatment started.
Community pharmacists offer accessible care, improve medication adherence, and build trust through education, vaccination support, and local health leadership.
Advertisement
Advertisement